STAAR SURGICAL CO (STAA) FY2026 10-K Annual Report
STAAR SURGICAL CO (STAA) 10-K annual report for fiscal year 2026, filed with SEC EDGAR on Mar 3, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
STAAR SURGICAL CO FY2026 10-K Analysis
Business Overview
- • Core business: development and sales of Implantable Collamer Lenses (ICLs) for treatment of myopia and refractive errors
- • New product emphasis: full launch of EVO+ premium larger optic lens in China and planned introduction of additional lens sizes for surgical flexibility
Management Discussion & Analysis
- • No revenue, profitability, segment, cash flow, or forward-looking data disclosed in the MD&A section provided
Risk Factors
- • Termination of Alcon Merger Agreement January 2026; $17.1 million Merger transaction costs in fiscal 2025
- • China macroeconomic downturn causing net sales drop from $313.9M in 2024 to $239.4M in 2025, with China distributor sales down from $162.3M to $77.8M
STAAR SURGICAL CO FY2026 Key Financial MetricsXBRL
Source: XBRL data from STAAR SURGICAL CO FY2026 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on STAAR SURGICAL CO
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.